WO2005097831A2 - Utilisations d'elements de liaison isoles capables de se lier specifiquement a des secretagogues - Google Patents
Utilisations d'elements de liaison isoles capables de se lier specifiquement a des secretagogues Download PDFInfo
- Publication number
- WO2005097831A2 WO2005097831A2 PCT/DK2005/000241 DK2005000241W WO2005097831A2 WO 2005097831 A2 WO2005097831 A2 WO 2005097831A2 DK 2005000241 W DK2005000241 W DK 2005000241W WO 2005097831 A2 WO2005097831 A2 WO 2005097831A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- ghrelin
- binding member
- binding
- individual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200400574 | 2004-04-07 | ||
DKPA200400574 | 2004-04-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005097831A2 true WO2005097831A2 (fr) | 2005-10-20 |
WO2005097831A3 WO2005097831A3 (fr) | 2005-12-22 |
Family
ID=34964219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2005/000241 WO2005097831A2 (fr) | 2004-04-07 | 2005-04-07 | Utilisations d'elements de liaison isoles capables de se lier specifiquement a des secretagogues |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005097831A2 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006045314A2 (fr) * | 2004-10-27 | 2006-05-04 | Gastrotech Pharma A/S | Utilisation d'un secretagogue de l'hormone de croissance en vue d'accroitre ou de maintenir la masse maigre et/ou pour le traitement de la maladie pulmonaire obstructive chronique |
WO2006129828A2 (fr) * | 2005-05-31 | 2006-12-07 | Canon Kabushiki Kaisha | Molecule de capture de substance active |
WO2021081326A1 (fr) * | 2019-10-25 | 2021-04-29 | Amgen Inc. | Compositions et procédés pour minimiser la perte de protéines à de faibles concentrations de protéines |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992017606A1 (fr) * | 1991-04-01 | 1992-10-15 | Brigham And Women's Hospital | Systeme de micro-dosage et secretagogue derive de polynucleaire neutrophile |
WO2001087335A2 (fr) * | 2000-05-17 | 2001-11-22 | Eli Lilly And Company | Procede d'inhibition selective de la ghreline |
EP1197496A1 (fr) * | 1999-07-23 | 2002-04-17 | Kenji Kangawa | Nouveaux peptides |
WO2004024183A1 (fr) * | 2002-09-12 | 2004-03-25 | Pharmexa A/S | Immunisation contre la ghreline autologue |
WO2005016951A2 (fr) * | 2003-06-04 | 2005-02-24 | Eli Lilly And Company | Anticorps contre la ghreline |
-
2005
- 2005-04-07 WO PCT/DK2005/000241 patent/WO2005097831A2/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992017606A1 (fr) * | 1991-04-01 | 1992-10-15 | Brigham And Women's Hospital | Systeme de micro-dosage et secretagogue derive de polynucleaire neutrophile |
EP1197496A1 (fr) * | 1999-07-23 | 2002-04-17 | Kenji Kangawa | Nouveaux peptides |
WO2001087335A2 (fr) * | 2000-05-17 | 2001-11-22 | Eli Lilly And Company | Procede d'inhibition selective de la ghreline |
WO2004024183A1 (fr) * | 2002-09-12 | 2004-03-25 | Pharmexa A/S | Immunisation contre la ghreline autologue |
WO2005016951A2 (fr) * | 2003-06-04 | 2005-02-24 | Eli Lilly And Company | Anticorps contre la ghreline |
Non-Patent Citations (4)
Title |
---|
ANANTH S ET AL: "Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 9, 1 May 1999 (1999-05-01), pages 2210-2216, XP002117563 ISSN: 0008-5472 * |
MACARTHUR C K ET AL: "A PEPTIDE SECRETED BY HUMAN ALVEOLAR MACROPHAGES RELEASES NEUTROPHIL GRANULE CONTENTS" JOURNAL OF IMMUNOLOGY, vol. 139, no. 10, 1987, pages 3456-3462, XP002352742 ISSN: 0022-1767 * |
SPERBER KIRK ET AL: "In vivo detection of a novel macrophage-derived protein involved in the regulation of mucus-like glycoconjugate secretion" AMERICAN REVIEW OF RESPIRATORY DISEASE, vol. 146, no. 6, 1992, pages 1589-1597, XP009056431 ISSN: 0003-0805 * |
STILES J D ET AL: "Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas" JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, NEW YORK, NY, US, vol. 56, no. 4, April 1997 (1997-04), pages 435-439, XP002117561 ISSN: 0022-3069 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006045314A2 (fr) * | 2004-10-27 | 2006-05-04 | Gastrotech Pharma A/S | Utilisation d'un secretagogue de l'hormone de croissance en vue d'accroitre ou de maintenir la masse maigre et/ou pour le traitement de la maladie pulmonaire obstructive chronique |
WO2006045314A3 (fr) * | 2004-10-27 | 2007-04-12 | Gastrotech Pharma As | Utilisation d'un secretagogue de l'hormone de croissance en vue d'accroitre ou de maintenir la masse maigre et/ou pour le traitement de la maladie pulmonaire obstructive chronique |
WO2006129828A2 (fr) * | 2005-05-31 | 2006-12-07 | Canon Kabushiki Kaisha | Molecule de capture de substance active |
WO2006129828A3 (fr) * | 2005-05-31 | 2007-02-15 | Canon Kk | Molecule de capture de substance active |
US7875465B2 (en) | 2005-05-31 | 2011-01-25 | Canon Kabushiki Kaisha | Target substance capturing molecule |
WO2021081326A1 (fr) * | 2019-10-25 | 2021-04-29 | Amgen Inc. | Compositions et procédés pour minimiser la perte de protéines à de faibles concentrations de protéines |
Also Published As
Publication number | Publication date |
---|---|
WO2005097831A3 (fr) | 2005-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3366644B2 (ja) | 部分的成長ホルモン不感受性症候群の治療 | |
JP6254146B2 (ja) | 代謝障害を治療するための組成物および方法 | |
US10905772B2 (en) | Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR) | |
EP3362477B1 (fr) | Protéines de liaison d'antigène qui activent le récepteur de la leptine | |
Root et al. | Clinical pharmacology of human growth hormone and its secretagogues | |
CN110117329B (zh) | 包含趋化因子与结合伴侣的融合多肽及其用途 | |
US10172918B2 (en) | SorCS1 for the treatment of obesity | |
US7612163B1 (en) | Prokineticin 2β peptide and its use | |
US20240043517A1 (en) | Anti-gdf15 antibody and a dosage regimen for the treatment of cancer | |
US20200261490A1 (en) | Pappalysin regulator | |
WO2005097831A2 (fr) | Utilisations d'elements de liaison isoles capables de se lier specifiquement a des secretagogues | |
US8703139B2 (en) | Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases | |
WO2005097830A2 (fr) | Utilisations d'elements de liaison isoles capables de reduire l'activite biologique de composes secretagogues | |
WO2013103783A1 (fr) | Anticorps murins il-13 | |
US20060051366A1 (en) | Use of soluble CD26 as inhibitor of angiogenesis and inflammation | |
WO2005097174A2 (fr) | Utilisations de combinaisons de secretagogue gh et d'une hormone de croissance | |
ES2224231T3 (es) | Anticuerpos monoclonales que se unen a la hormona del crecimiento humana (hgh). | |
US20240026009A1 (en) | Antibodies to galectin-3 and methods of use thereof | |
WO2005110454A2 (fr) | Elements de liaison protecteurs de pyy, pour le traitement des troubles du metabolisme | |
EP2986641B1 (fr) | Anticorps anti-ghrelin et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |